
Amy Jo Chien

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8607147/publications.pdf Version: 2024-02-01



AMY IO CHIEN

#	Article	IF	CITATIONS
1	Emerging immunotherapeutic strategies for the treatment of breast cancer. Breast Cancer Research and Treatment, 2022, 191, 243-255.	2.5	4
2	Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship–Associated Distress: Survey Study. JMIR Cancer, 2022, 8, e31756.	2.4	0
3	Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions. Current Breast Cancer Reports, 2021, 13, 164-170.	1.0	1
4	Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials Journal of Clinical Oncology, 2021, 39, 1092-1092.	1.6	3
5	Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. Journal of Assisted Reproduction and Genetics, 2021, 38, 2455-2463.	2.5	8
6	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. JAMA Oncology, 2021, 7, 1654.	7.1	42
7	The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. Npj Breast Cancer, 2021, 7, 156.	5.2	8
8	Fertility preservation before breast cancer treatment appears unlikely to affect diseaseâ€free survival at a median followâ€up of 43Âmonths after fertilityâ€preservation consultation. Cancer, 2020, 126, 487-495.	4.1	43
9	Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. Npj Breast Cancer, 2020, 6, 48.	5.2	21
10	Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. JAMA Oncology, 2020, 6, 1355.	7.1	119
11	Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. Cancers, 2020, 12, 1511.	3.7	9
12	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial. Journal of Clinical Oncology, 2020, 38, 1059-1069.	1.6	69
13	A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. Npj Breast Cancer, 2019, 5, 17.	5.2	19
14	Fertility preservation with ovarian stimulation and time to treatment in women with stage Il–III breast cancer receiving neoadjuvant therapy. Breast Cancer Research and Treatment, 2017, 165, 151-159.	2.5	47
15	Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Human Reproduction, 2017, 32, 2123-2129.	0.9	59
16	Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 2016, 375, 23-34.	27.0	467
17	Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal of Medicine, 2016, 375, 11-22.	27.0	301
18	A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Research and Treatment, 2016, 155, 521-530.	2.5	27

Amy Jo Chien

#	Article	IF	CITATIONS
19	Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Research and Treatment, 2015, 153, 173-181.	2.5	17
20	Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial Journal of Clinical Oncology, 2015, 33, 524-524.	1.6	27
21	Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer, 2012, 118, 1710-1717.	4.1	430
22	Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired. Seminars in Oncology, 2008, 35, S1-S14.	2.2	75